Singapore HSA updated Guidance for Post-marketing Vigilance Requirements for Therapeutic Products and Cell, Tissue and Gene Therapy Products (CTGTP), effective 1 April 2026.
Apart from editorial changes made, the following areas
Singapore HSA updated Guidance for Post-marketing Vigilance Requirements for Therapeutic Products and Cell, Tissue and Gene Therapy Products (CTGTP), effective 1 April 2026.
Apart from editorial changes made, the following areas
Singapore HSA announces that electronic Common Technical Document (eCTD) format will be officially accepted for Therapeutic Products regulatory dossier submission with effect from 1 April 2026. Companies may continue with
Health Sciences Authority (HSA) has updated the Guidance on Cell, Tissue or Gene Therapy Product (CTGTP) Registration and Variation Applications in Singapore, as well as the related Minor Variation (MIV)
The Medical Device Authority (MDA) of Malaysia and the Health Sciences Authority (HSA) of Singapore signed a Memorandum of Understanding (MoU) during the 14th ASEAN Medical Device Committee (AMDC) Meeting
As part of HSA’s ongoing initiative to improve regulatory efficiency and enhance clarity in Singapore’s regulatory requirements and processes, the Vigilance and Compliance Branch, Health Products Regulation Group, has updated
Malaysia NPRA has release circular on Drug Registration Guidance Document (DRGD) guideline Updates on Variation application processing timeline for all registered products including all product categories and Introduce Reliance Mechanism
As part of Singapore HSA’s ongoing initiative to improve regulatory efficiency and enhance clarity in regulatory requirements and processes, the Therapeutic Products Branch (TPB), Health Products Regulation Group, has updated
The revised guideline includes several key changes:
Document title has been updated to include machine learning-enabled medical devices.
New and revised definitions have been added for “Machine Learning”, “AIMD”, “Cybersecurity”,
Malaysia MDA has released an updated version of its Conformity Assessment Body (CAB) Guide for Conducting Conformity Assessment by Way of Verification.
As part of the revision, the MDA has expanded